blt1gdwh92y12imr3d7olw0p7ga63n

💡 AI Summary & Key Takeaways

– Metformin remains a common first-line drug unless contraindicated.
– SGLT2 inhibitors and GLP-1 receptor agonists are favored when heart, kidney or weight benefits are needed.
– Know the key adverse effects of each class.

Type 2 Diabetes Medications: Choosing the Right Drug

Type 2 diabetes medications are a major exam topic because drug choice now depends on more than glucose. Guidelines emphasize heart disease, heart failure, kidney disease, weight and risk of hypoglycemia. Learn the main classes, what each one adds and what each one can harm.

Lifestyle and targets

Lifestyle changes, including diet, exercise and weight loss, remain the foundation. Glycemic targets are individualized, with a common goal of around 7 percent for many adults and less strict targets for those with limited life expectancy or high hypoglycemia risk.

Metformin

Often first-line. It lowers hepatic glucose production, is weight neutral, has a low risk of hypoglycemia and is inexpensive. Common side effects are gastrointestinal upset, and long-term use can reduce vitamin B12 levels. Avoid it in severe kidney impairment because of the risk of lactic acidosis, and follow local guidance around contrast imaging and acute illness.

SGLT2 inhibitors

Examples include empagliflozin and dapagliflozin. They lower glucose by increasing urinary glucose excretion and provide benefits in heart failure and chronic kidney disease. Risks include genital fungal infections, volume depletion and euglycemic ketoacidosis.

GLP-1 receptor agonists

Examples include semaglutide and liraglutide. They promote weight loss, have cardiovascular benefit in many patients and cause gastrointestinal effects. They are avoided in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and caution is needed in those with pancreatitis.

DPP-4 inhibitors

Examples include sitagliptin. They are weight neutral and well tolerated but have modest efficacy. Some agents carry a caution in heart failure.

Sulfonylureas

They stimulate insulin release, are effective and inexpensive but cause hypoglycemia and weight gain, especially in older adults and those with kidney impairment.

Thiazolidinediones

Pioglitazone improves insulin sensitivity but can cause fluid retention and is avoided in heart failure. Fractures are another concern.

Insulin

Used when glucose control is inadequate or when there is marked hyperglycemia or catabolic symptoms. Know the principles of basal and prandial regimens and hypoglycemia management.

A classic exam pattern

A patient with type 2 diabetes and heart failure with reduced ejection fraction needs an additional agent. A sodium-glucose cotransporter 2 inhibitor is a strong answer because of its benefit in heart failure.

Study tips

This article is for exam revision and does not replace current clinical guidelines. Practice endocrine cases in the Namazj free trial.

Leave a Reply

Your email address will not be published. Required fields are marked *